Drug Class Review on Targeted Immune Modulators: Final Report [Internet]

Gerald Gartlehner; Richard A Hansen; Patricia Thieda; Beth Jonas; Kathleen N Lohr; Tim Carey

Drug Class Review on Targeted Immune Modulators: Final Report [Internet]

Review

Portland (OR): Oregon Health & Science University; 2007 Jan.

Drug Class Reviews.

Authors

Gerald Gartlehner¹, Richard A Hansen¹, Patricia Thieda¹, Beth Jonas¹, Kathleen N Lohr¹, Tim Carey¹

Affiliation

¹ RTI-UNC Evidence-based Practice Center, Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, 725 Airport Road, CB# 7590, Chapel Hill, NC 27599-7590, Tim Carey, MD, MPH, Director

PMID: 20496444
Bookshelf ID: NBK10567

Excerpt

Targeted immune modulators are used in the treatment of certain types of immunologic and inflammatory diseases, including rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), plaque psoriasis, Crohn's disease, and ulcerative colitis (UC). These drugs work by selectively blocking mechanisms involved in the inflammatory and immune response. The purpose of this review is to help policy makers and clinicians make informed choices about the use of targeted immune modulators.

Sections

Publication types

Review

Grants and funding

The funding source, the Center for Evidence-based Policy, is supported by 17 organizations, including 15 state Medicaid programs. These organizations selected the topic and had input into the Key Questions for this review. The content and conclustions of this review are entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.